Monday, April 18 Scientific Platform Sessions 3:30 p.m.–5:30 p.m. Scientific Platform Sessions S24: Clinical Outcomes and Treatment Strategies in Multiple Sclerosis 3:30 p.m. S24.001 Predicting the End of Symptomatic Relapses and Disease Modifying Treatment Use Decisions in Progressive Multiple Sclerosis —Martina Novotna, Brittani Conway, Burcu Zeydan, M. Paz Soldan, Nuhad Abou Zeid, Nilufer Kale, Melih Tutuncu, Orhun Kantarci 3:45 p.m. S24.002 Can We Stop Immunomodulatory Treatment in Secondary Progressive MS? —Julien Bonenfant, Veronique Deburghgraeve, Emmanuelle Le Page, Gilles Edan, Anne Kerbrat, Bajeux Emma 4:00 p.m. S24.003 Switch Strategies in RRMS: A Real-Life Multi Center Study —Francesco Sacc, Alessio Signori, Giorgia Teresa Maniscalco, Roberta Lanzillo, Salvatore Lo Fermo, Pietro Annovazzi, Luca Prosperini, Eleonora Cocco, Simona Bonavita, Valentina Torri Clerici, Alice Laroni, Anna Maria Repice, Ignazio Roberto Zarbo, Cerqua Raffaella, Alessia Di Sapio, Simona Pontecorvo, Marinella Clerico, Luigi Lavorgna, Caterina Barrillà, Cinzia Cordioli, Fabio Gallo, Maria Pia Sormani 4:15 p.m. S24.004 Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience — Brandi Vollmer, Kavita Nair, Stefan Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez 4:30 p.m. S24.005 Interferon-Beta Exposure During First Trimester in Women with Multiple Sclerosis - A Prospective Cohort Study from the German Multiple Sclerosis and Pregnancy Registry —Sandra Thiel, Sylvia Menck, Birte Elias-Hamp, Ralf Gold, Kerstin Hellwig 4:45 p.m. S24.006 Pregnancy and Fetal Outcomes After In Utero Exposure to Natalizumab in Patients with Multiple Sclerosis: A Prospective, Nation-Wide, Controlled Study —Marta Giannini, Emilio Portaccio, Bahia Hakiki, Pasto' Luisa, Lorenzo Razzolini, Righini Isabella, Carla Tortorella, Maria Trojano, Eleonora Cocco, Maurizio Melis, Marrosu Maria Giovanna, Valeria Di Tommaso, Deborah Farina, Alessandra Lugaresi, Pietro Annovazzi, Angelo Ghezzi, Claudio Gasperini, Alfonso Iudice, Roberta Fantozzi, Paolo Bellantonio, Silvia Messina, Francesco Patti, Chiavazza Carlotta, Paola Cavalla, Alessandra Protti, Rocco Totaro, Carlo Pozzilli, Laura De Giglio, Antonio Uccelli, Arianna Sartori, Antonio Bosco, Roberta Lanzillo, Vincenzo Brescia Morra, Maria Pia Amato 5:00 p.m. S24.007 Age Related Multiple Sclerosis Severity Score: Disability Ranked by Age —Ali Manouchehrinia, Westerlind Helga, Elaine Kingwell, Feng Zhu, Robert Carruthers, Ryan Ramanujam, Ban Maria, Anna Glaser, Stephen Sawcer, Helen Tremlett, Jan Hillert 5:15 p.m. S24.008 Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program — Jiwon Oh, Anat Achiron, Christina Chambers, Edward Fox, Pamela McCombe, Susana Otero, David Margolin, Linda Kasten, D Alastair Compston S25: Movement Disorders: Huntington's Disease 3:30 p.m. Presentation of the Movement Disorders Research Award Sponsored by the American Academy of Neurology and the Parkinson’s Disease Foundation through an endowment. Recipient: Susan B. Bressman, MD, FAAN New York, NY 4:00 p.m. S25.003 Intermediate CAG Repeats in Huntington´s Disease. A Longitudinal Analysis of the European Huntington´s Disease Network REGISTRY Cohort — Esther Cubo, Maria Antonia Ramos-Arroyo, Saul Martinez-Horta, Asunción Martinez- Descalls, Cecilia Gil-Polo 4:15 p.m. S25.004 PRE-CELL: Clinical and Novel Biomarker Measures of Disease Progression in a Lead-In-Observational Study for a Planned Phase 1 Trial of Genetically- Modified Mesenchymal Stem Cells Over-Expressing BDNF in Patients with Huntington’s Disease —Vicki Wheelock, Teresa Tempkin, Alexandra Duffy, Amanda Martin, Lisa Mooney, Ashok Dayananthan, Lorin Scher, Sarah Farias, David Swadell, Charles DeCarli, James Brunberg, Chin- Shang Li, Yu Liu, Mark Yarborough, Julie Stout, miriam Moscovitch-Lopatin, Steven Hersch, Kyle Fink, Geralyn Annett, Jan Nolta 4:30 p.m. S25.005 Enroll-HD: A Global Clinical Research Platform for Huntington’s Disease — Tiago Mestre, Cheryl Fitzer-Attas, Joseph Giuliano, Bernhard Landwehrmeyer, Cristina Sampaio 4:45 p.m. S25.006 Rating Swallowing Function in Patients with Huntington Disease Enrolled in the First-HD Study —Daniel Claassen, Samuel Frank, David Stamler, Victor Sung, Sarah Janicki, David Oakes, Christina Vaughan, Claudia Testa 5:00 p.m. S25.007 Mesenchymal Stem Cells Engineered to Overexpress Brain-Derived Neurotrophic Factor As a Proposed Therapeutic for Huntington’s Disease —Vicki Wheelock, Kari Pollock, Heather Dahlenberg, Hayley Nelson, Kyle Fink, Whitney Cary, Kyle Hendrix, Geralyn Annett, Audrey Torrest, Peter Deng, Josh Gutierrez, Catherine Nacy, Karen Pepper, Stefanos Kalomoiris, Johnathon Anderson, Jeannine McGee, William Gruenloh, Brian Fury, Gerhard Bauer, Alexandra Duffy, Teresa Tempkin, Jan Nolta 5:15 p.m. S25.008 First-In-Human Stem Cell Trials in Huntington’s Disease: A Bioethics Survey —Alexandra Duffy, Teresa Tempkin, Amanda Martin, Meaghan O’Keefe, Marsha Michie, Mark Yarborough, Vicki Wheelock S26: Headache 3:30 p.m. Presentation of the Harold Wolff-John Graham: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals. Recipient: Catherine Chong, PhD Phoenix, AZ 3:45 p.m. S26.002 Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension —Robert Lenz, David Dodick, Peter Goadsby, Stephen Silberstein, Uwe Reuter, Messoud Ashina, Joel Saper, Roger Cady, Feng Zhang, Marie-Louise Trotman, Julie Dietrich, Hong Sun 4:00 p.m. S26.003 Emotional Abuse History and Migraine Among Young Adults: Results from The Add Health Dataset —Gretchen Tietjen, Monita Karmakar, Aliaksander Amialchuk 4:15 p.m. S26.004 Factors Predicting the Response to the First Epidural Blood Patch in Spontaneous Intracranial Hypotension —Jr-Wei Wu, Shu-Shya Hseu, Jong-Ling Fuh, Jiing-Feng Lirng, Yen- Feng Wang, Wei-Ta Chen, Shuu-Jiun Wang 4:30 p.m. S26.005 Modifications of Gray Matter Volume in Migraine Patients Over Four Years: A Tensor-Based Morphometry Study — Roberta Messina, Maria Rocca, Bruno Colombo, Elisabetta Pagani, Andrea Falini, Giancarlo Comi, Massimo Filippi 4:45 p.m. S26.006 Inflammation and Abnormal Trigeminal Sensory Processing in Obese Mice — Ana Recober-Montilla, Heather Rossi 5:00 p.m. S26.007 Peripheral and Central Nervous System Distribution of a CGRP Neutralizing Antibody [ 125 I]-LY2951742 in Male Rats —Michael Johnson, Bernice Ellis, Deanna Maren, S. Michelle Morin, Victor Wroblewski, Kirk Johnson 5:15 p.m. S26.008 Delivery Outcomes After Acute Migraine Treatment in Pregnancy — Matthew Robbins, Tracy Grossman, Shravya Govindappagari, Ashlesha Dayal Plan Your Annual Meeting Experience with Convenient Online Program Search Planning your Annual Meeting week just got easier! Gain insight with helpful tips and suggested programs that may be of most interest to you—and applicable to your career. AAN.com/view/SearchAM 86 2016 AAN Annual Meeting Abstract Listing
Industry Therapeutic Updates Industry Therapeutic Updates Saturday, April 16, 2016, Tuesday, April 19, 2016, and Wednesday, April 20, 2016 Starting at 7:00 p.m. Registration is free and open to registered Annual Meeting attendees. Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you the opportunity to learn about current therapies and projects in the industry pipeline. Saturday, April 16, 2016 ACADIA Pharmaceuticals Inc. Beyond Motor Symptoms: Parkinson’s Disease Psychosis, Expert Perspectives in Neurology and Psychiatry Location: Fairmont Waterfront Waterfront Ballroom ABC Tuesday, April 19, 2016 UCB, Inc. Clinical Debate: Is Shorter Time to Control in Chronic Neurological Disorders a Need or a Want? Location: Westin Bayshore Bayshore Grand Ballroom Mon · April 18 AbbVie Inc. Emerging Concepts in Advanced Parkinson’s Disease Location: Hyatt Regency Vancouver Ballroom DEF Biogen Location: Pan Pacific Hotel Crystal Ballroom Genentech Evolving Perspectives on Disease Activity: What Is Lying Beneath the Surface? Location: Hyatt Regency Vancouver Regency Ballroom C Eisai Canada Location: Westin Bayshore Stanley Park Ballroom IMPAX Pharmaceuticals Location: Hyatt Regency Vancouver Regency Ballroom AB Sunovion Pharmaceuticals Inc. Industry Therapeutic Update: A Live Panel Event Location: Vancouver Marriott Downtown Pinnacle Ballroom Wednesday, April 20, 2016 Sanofi Genzyme Preserving Brain and Function in Multiple Sclerosis Location: Westin Bayshore Bayshore Grand Ballroom Novartis Pharma AG A switch in time: taking charge of MS disease activity Location: Fairmont Waterfront Waterfront Ballroom ABC RSVP is recommended for these events. Please visit AAN.com/view/ITU for more information. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
Change language